Skip to main content

Search

Reset all filters
98 Result(s)
Sort by

CONTINUUM

CONTINUUM

CONTINUUM, a collaborative project, investigates how digital technology can help healthcare professionals manage complex patient cases at home. Keep reading.
EMPA-KIDNEY trial showed significant benefit of JARDIANCE® (empagliflozin) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people living with chronic kidney disease

EMPA-KIDNEY trial showed significant benefit of JARDIANCE® (empagliflozin) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people living with chronic kidney disease

EMPA-KIDNEY, the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease, provides new evidence for patients commonly seen in clinical practice 1,2,3 Phase III trial also demonstrated a 14% statistically significant reduction
Home Health Monitoring

Home Health Monitoring

Read more about the HHM Project that provides a community-based home health monitoring digital solution for people living with chronic conditions.
Tereza Urbankova

Tereza Urbankova

Tereza Urbankova, a senior manager in Global Media Relations, says that the teams feel really tight knit and always supporting each other.
Simon Manyara

Simon Manyara

Simon Manyara works with our culture and sustainability team towards making a positive social impact and creating a sustainable future.
Work life wellness

Work life wellness

We provide you with a range of benefits and services, including counselling, exercise classes, social events to help you stay mentally and physically fit.
JARDIANCE® (empagliflozin) becomes the first and only approved treatment in Canada for adults with chronic heart failure regardless of ejection fraction

JARDIANCE® (empagliflozin) becomes the first and only approved treatment in Canada for adults with chronic heart failure regardless of ejection fraction

JARDIANCE® is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death and hospitalization for chronic heart failure1 Heart failure represents a significant, growing disease burden
ABILD

ABILD

ABILD partnership aims at enhancing health innovation projects to comprehend care gaps in diagnosis, treatment, and access for Albertans with progressive fibrosing ILD.